



# 2023-2024 RESPIRATORY VIRUS AND VACCINE UPDATES

SUSAN DUCORE, DNP, MSN, RN, PHN

CA AREA NURSE CONSULTANT/PROJECT OFFICER

AREA IMMUNIZATION COORDINATOR

CAIHS PROGRAM DIRECTORS' MEETING \_ OCTOBER 4, 2023

# RESPIRATORY VIRAL SEASON - FALL/WINTER VACCINE PREVENTABLE DISEASES- EPIDEMIOLOGY

- **SEASONAL INFLUENZA (FLU)**
  - AVERAGE 12,000-52,000 DEATHS AND OVER 200,000 HOSPITALIZATIONS ANNUALLY
- **RESPIRATORY SYNCYTIAL VIRUS (RSV)**
  - AVERAGE 58,000-80,000 HOSPITALIZATIONS (<AGE 5Y) ANNUALLY
  - LEADING CAUSE OF HOSPITALIZATION IN INFANTS IN THE UNITED STATES
  - AVERAGE 60,000-160,000 HOSPITALIZATIONS (>65Y) ANNUALLY
- **SARS-COV-2 (COVID-19)**
  - AGE-ADJUSTED COVID DEATH RATE = 61.3 PER 100,000 PERSONS
  - EXCESS MORTALITY IN THE U.S. > 1 MILLION PERSONS TO DATE
  - CURRENT DEATH RATE IN THE U.S. > 600/WEEK

# 2023-2024 FALL RESPIRATORY VIRUSES

## FLU

- ACUTE RESPIRATORY INFECTION CAUSED BY INFLUENZA VIRUSES
- HIGHLY CONTAGIOUS; SPREAD THROUGH RESPIRATORY DROPLETS
- **VIRUS STRAIN CAN CHANGE FROM YEAR TO YEAR** – FLU VACCINE COMPONENTS ARE DETERMINED ANNUALLY BASED ON DOMINANT CIRCULATING STRAIN (S)
- **ANNUAL FLU VACCINATION IS BEST AVAILABLE METHOD OF PROTECTION** AGAINST INFLUENZA AND COMPLICATIONS
- **OCTOBER TO APRIL SEASON** (JANUARY AND FEBRUARY OFTEN PEAK OF INFECTIONS)

## COVID-19

- CAUSED BY THE SARS-COV-2 VIRUS
- HIGHLY CONTAGIOUS; SPREAD THROUGH RESPIRATORY DROPLETS
- CAN INFECT PERSONS OF ALL AGES
- **VACCINES AVAILABLE FOR ALL PERSONS  $\geq$ 6 MOS. OF AGE**
- **AT INCREASED RISK:** PREGNANT AND POSTPARTUM WOMEN, PERSONS WITH CHRONIC DISEASE, RESPIRATORY AND OTHER, CHILDREN, OLDER ADULTS\*

## RSV

- CAUSED BY THE RESPIRATORY SYNCYTIAL VIRUS
- HIGHLY CONTAGIOUS; SPREAD THROUGH RESPIRATORY DROPLETS
- SYMPTOMS CAN BE MORE SEVERE IN **INFANTS AND OLDER ADULTS** WITH CHRONIC MEDICAL CONDITIONS AND/ OR WEAKENED IMMUNE SYSTEMS
- **RESEARCH SUGGESTS A HIGHER INCIDENCE OF SEVERE RSV DISEASE IN AI/AN CHILDREN \*\***
- VACCINES AND MEDICATIONS ARE APPROVED OR AUTHORIZED FOR INFANTS AND ADULTS FOR **CURRENT SEASON**
- MOST ILLNESSES OCCUR DURING FALL AND WINTER, HOWEVER CASES START INCREASING AS EARLY AS JULY
- **AS OF SEPTEMBER 22, 2023, CDC RECOMMENDS AN RSV VACCINE DURING WEEKS 32–36 OF PREGNANCY TO PROTECT BABIES FROM SEVERE RSV.**

\* At risk populations similar for COVID-19, Flu, and RSV Viruses

\*\*Atwell JE, Hartman RM, Parker D, et al.; RSV Among American Indian and Alaska Native Children: 2019 to 2020. Pediatrics. 2023;152(2): e2022060435

# PREVENTING A “TRIPLEDEMIC” TOGETHER!

- **THE 2023 FALL RESPIRATORY SEASON HAS ARRIVED**
  - PLANNING FOR VACCINE ROLL OUTS SHOULD BE WELL UNDERWAY
- **GOOD NEWS!** THIS IS THE FIRST FALL AND WINTER VIRUS SEASON WHERE **VACCINES ARE AVAILABLE FOR THE THREE MAJOR RESPIRATORY VIRUSES –COVID-19, RSV AND FLU.**
- **COADMINISTRATION OF ALL VACCINES IS SUPPORTED**
  - **ADVISORY COMMITTEE ON IMMUNIZATION PRACTICE (ACIP)** SPECIFICALLY RECOMMENDS THAT ALL RECOMMENDED VACCINES MAY BE **ADMINISTERED SIMULTANEOUSLY.**
    - THIS INCLUDES **RSV, INFLUENZA VACCINES, COVID-19 VACCINES,** PNEUMOCOCCAL VACCINES, TD/TDAP, ZOSTER VACCINES AND OTHER AS APPROPRIATE
  - **COADMINISTRATION OF MULTIPLE VACCINES AT THE SAME VISIT MAY INCREASE REACTOGENICITY**

# 2023-2024 COVID-19 VACCINE REGULATORY ACTION

- **COVID-19 VACCINE REGULATORY ACTION:**

- 9/11/2023: UPDATED COVID-19 VACCINES AUTHORIZED BY FOOD AND DRUG ADMINISTRATION (FDA)
  - **THE NEW EUA ISSUANCE IMMEDIATELY DE-AUTHORIZES THE PREVIOUSLY APPROVED BIVALENT COVID VACCINES**
  - **NEWLY APPROVED XBB STRAIN VACCINES ARE COMMERCIALIZED VACCINES**
    - **WILL NOT BE US GOVERNMENT (USG) SUPPLIED; NOW COMMERCIALY AVAILABLE**
    - **WILL NOT BE SUBJECT TO REPORTING UNDER THE IHS CDC COVID VACCINE REPORTING AGREEMENT**

# SUMMARY FROM ACIP DATA REVIEW – COVID-19

- IN SHORT – **VACCINES ARE SAFE AND EFFECTIVE!** HOWEVER THERE IS SIGNIFICANT **WANING OF IMMUNITY OVER TIME.**
- IT'S BEEN NEARLY A YEAR SINCE MOST PEOPLE RECEIVED A COVID-19 VACCINE UPDATE, AND UPTAKE WAS VERY LOW (**ONLY 15% ON AVERAGE OVERALL UPTAKE, WITH HIGHER OR LOWER UPTAKE IN VARIOUS AGE GROUPS**)
- CLINICAL AND PRE-CLINICAL TRIALS FOR **UPDATED XBB.1.5 VACCINES SHOW AN IMPROVED RESPONSE AGAINST CURRENTLY CIRCULATING VARIANTS** AND VARIANTS THAT MAY MAKE THEIR WAY TO THE U.S.
- OVERALL, **BENEFITS OF VACCINATION OUTWEIGH THE RISKS** (INCLUDING RISK OF MYOCARDITIS)

# 2023-2024 FORMULATION COVID-19 VACCINES

- PFIZER – BIONTECH COVID-19 VACCINE – MRNA VACCINE
  - MODERNA COVID-19 VACCINE – MRNA VACCINE
  - NOVAVAX COVID-19 VACCINE, ADJUVANTED - EUA 10/2023
- 
- SOURCE: [HTTPS//CDC.GOV/COVID-19](https://cdc.gov/covid-19)

# 2023-2024 COVID-19 VACCINES: A REVIEW OF RECENT UPDATES

Pfizer and  
Moderna XBB.1.5  
monovalent  
vaccines were  
recommended

- VRBPAC, FDA, ACIP, CDC all endorsed
- 12yrs+ has FULL FDA approval
- 6 months – 11 years is still authorized under EUA
- Bivalent Pfizer and Moderna vaccines are NO LONGER authorized effective 9/11/23

Simplified and  
streamlined  
vaccine  
recommendations

- EVERYONE  $\geq$  6 months of age recommended to get a dose of UPDATED 2023-2024 COVID XBB.1.5 vaccine
- Must be 2 months since last dose
- Only children 6 months – 4 years are recommended to complete a full series if they did not complete an initial COVID-19 series (2 doses for Moderna and 3 doses for Pfizer)

## COVID Vaccine Code Summary Crosswalk 2023-2024 COVID Vaccine Formulations

*Adopted from AMA Appendix Q and CDC Vaccine Code Crosswalk*

Manufacturer (MVX)	Product Label Tradename	Patient Age	CVX Short Description	CVX	Vaccine CPT	Administration CPT Code	Vaccine Presentation	Unit of Use (UoU) NDC	Unit of Sale (UoS) NDC	Cap/Label Color
Pfizer (PFR)	COMIRNATY COVID-19 Vaccine	12 years and older	COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL	309	91320	90480	VIAL, SINGLE-DOSE, 30 mcg/0.3 mL	00069-2362-01	00069-2362-10	Gray
							SYRINGE, PRE-FILLED, 30 mcg/0.3 mL	00069-2392-01	00069-2392-10	Gray
Pfizer (PFR)	Pfizer-BioNTech COVID-19 Vaccine	5 to 11 years	COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL	310	91319	90480	VIAL, SINGLE-DOSE, 10 mcg/0.3 mL	59267-4331-01	59267-4331-02	Blue
Pfizer (PFR)	Pfizer-BioNTech COVID-19 Vaccine	6 months to 4 years	COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL	308	91318	90480	VIAL, MULTI-DOSE, 3 DOSES, 3mcg / 0.3 mL AFTER DILUTION	59267-4315-01	59267-4315-02	Yellow
Moderna (MOD)	Spikevax COVID-19 Vaccine	12 years and older	COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL	312	91322	90480	VIAL, SINGLE-DOSE, 50 mcg/0.5 mL	80777-0102-04	80777-0102-95	Dark Blue cap, Blue label
							SYRINGE, PRE-FILLED, 50 mcg/0.5 mL	80777-0102-01	80777-0102-96	Blue
							BLISTER-SEALED SYRINGE, PRE-FILLED, 50 mcg/0.5 mL	80777-0102-01	80777-0102-93	Blue
Moderna (MOD)	Moderna COVID-19 Vaccine	6 months to 11 years	COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL	311	91321	90480	VIAL, SINGLE-DOSE, 25 mcg/0.25 mL	80777-0287-07	80777-0287-92	Dark Blue cap, Green label
Novavax (NVX) Pre-EUA	Novavax COVID-19 Vaccine, Adjuvanted	12 years and older	COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL <i>Pre-EUA</i>	313	91304	90480	VIAL, MULTI-DOSE, 5 DOSES, 5 mcg/0.5 mL	80631-0105-01	80631-0105-02	Blue

*Updated 09/14/2023*

Adapted from:

<https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html>

<https://www.ama-assn.org/system/files/covid-19-immunizations-appendix-q-table.pdf>

# COVID-19 VACCINE – PROCUREMENT PATHWAYS

- **COMMERCIALIZED/PURCHASED PRIVATE SUPPLY VACCINE**
  - REDUCED PACKAGE SIZES
  - MORE CONVENIENT DOSAGE FORMS
    - SINGLE DOSE VIALS, PRE-FILLED SYRINGES
- **IHS NATIONAL SERVICE SUPPLY CENTER (NSSC): NSSC NEW CUSTOMER INFORMATION:**
  - IF YOUR FACILITY IS INTERESTED IN BECOMING A REGULAR CUSTOMER OF THE NSSC, PLEASE COMPLETE A [NEW CUSTOMER APPLICATION FORM](#) (FILLABLE) [PDF - 698 KB] AND E-MAIL TO THE [NSSC CUSTOMER SERVICE LIAISON](#) OR FAX TO 405-951-6057 ;  
[HTTPS://WWW.IHS.GOV/SITES/NSSC/THEMES/RESPONSIVE2017/DISPLAY\\_OBJECTS/DOCUMENTS/CUSTOMER/NSSC\\_NEWCUSTOMERAPPLICATIONFORM.PDF](HTTPS://WWW.IHS.GOV/SITES/NSSC/THEMES/RESPONSIVE2017/DISPLAY_OBJECTS/DOCUMENTS/CUSTOMER/NSSC_NEWCUSTOMERAPPLICATIONFORM.PDF)
- **THE VFC PROGRAM**
  - FOR ELIGIBLE CHILDREN 0-18YRS (AMERICAN INDIAN/ALASKA NATIVE CHILDREN, UNINSURED, AND CHILDREN ON MEDICAID)
- **THE "HHS BRIDGE PROGRAM"**
  - THE BRIDGE PROGRAM WILL PROVIDE NO COST COVID VACCINE FOR UNDER AND UNINSURED ADULTS IN THE U.S. AT PARTICIPATING PARTNERS, INCLUDING RETAIL PHARMACIES, FQHCs, HEALTH DEPARTMENTS.
- VFC AND BRIDGE PROGRAMS REQUIRE **DOSE-LEVEL ACCOUNTABILITY.**
  - FOR EXAMPLE, A PHARMACY CARRYING ALL FDA-APPROVED PRODUCTS MAY ACTUALLY HAVE NINE COVID-19 VACCINE SUPPLIES ON THE SHELF

# COVID-19 THERAPEUTICS

- **COMMERCIALIZATION TIMELINE FOR THE ORAL THERAPEUTICS**

- MOLNUPIRAVIR – EXPECTED TO TRANSITION TO THE COMMERCIAL MARKET IN NOVEMBER 2023
- PAXLOVID AND RENAL PAXLOVID – AMPLE SUPPLY REMAINS AVAILABLE FROM THE US GOVERNMENT
- **PAXLOVID AND RENAL PAXLOVID USG SUPPLY WILL REMAIN AVAILABLE IN HPOP FOR AN EXTENDED PERIOD OF TIME, COMMERCIALIZATION TIMELINE TBD**

# PROCUREMENT OF COVID VACCINES \_PRIVATE PURCHASE


MODERNA:

[HTTPS://MODERNADIRECT.COM/AUTHORIZED-DISTRIBUTOR](https://modernadirect.com/authorized-distributor)

PFIZER:

[HTTPS://WWW.PFIZERPRO.COM/ORDER](https://www.pfizerpro.com/order)

NOVAVAX: NO UPDATES ON PRIVATE PROCUREMENT – EUA 10/2023

The background is a light blue gradient. In the top-left and bottom-right corners, there are several realistic-looking water droplets of various sizes, some overlapping. The droplets have highlights and shadows, giving them a three-dimensional appearance.

# 2023-2024 SEASONAL INFLUENZA VACCINES AND SURVEILLANCE UPDATES

# WEEK 38: 09/17/2023 – 09/23/2023 INFLUENZA-LIKE ILLNESS SURVEILLANCE (ILI)REPORT

WEEKLY ILI REPORTS ARE DISTRIBUTED BY INDIAN HEALTH SERVICE DIVISION OF EPIDEMIOLOGY AND DISEASE PREVENTION AND PASSED ALONG BY EMAIL TO CA AREA TRIBAL HEALTH PROGRAM IMMUNIZATION COORDINATORS AND PROGRAM DIRECTORS

- REPORTS ARE GENERATED THROUGH IHS INFLUENZA AWARENESS SYSTEM (IIAS)
- CA AREA PARTICIPATING I/T/U SITE DATA IS INCLUDED
- **CALIFORNIA**, GREAT PLAINS, NASHVILLE, NAVAJO, AND PORTLAND AREAS REPORT **INFLUENZA VACCINATION RATES ABOVE THE NATIONAL RATE FOR ALL AGE GROUPS FOR WEEK 38.**

SOURCE: INFECTIOUS DISEASE BRANCH, IHS DIVISION OF EPIDEMIOLOGY AND DISEASE PREVENTION (DEDP)

# 2023-2024 INFLUENZA VACCINE DISTRIBUTERS OR MANUFACTURERS

Influenza Vaccine Availability Tracking System (IVATS) Report  
2023-2024 Influenza Vaccination Season

Distributor or Manufacturer			Influenza Vaccine Product												
Date of last report	Name of distributor or manufacturer	Where to place order (Please note that some distributors and manufacturers may have return policies. Ask at the time of your order.)	GlaxoSmithKline		AstraZeneca	Seqirus					Sanofi				
			Fluarix (IIV4)	FluLaval (IIV4)	FluMist (LAIV4)	Afluria (IIV4)	Flud (aIIV4)	Flucelvax (ccIIV4)			Flublok (RIV4)	Fluzone (IIV4)		Fluzone High-Dose (HD-IIV4)	
			Single-dose syringe (0.5 mL)	Single-dose syringe (0.5 mL)	Single-dose nasal sprayer	Single-dose syringe (0.5 mL)	Multi-dose vial (5.0 mL)	Single-dose syringe (0.5 mL)	Single-dose syringe (0.5 mL)	Multi-dose vial (5.0 mL)	Single-dose syringe (0.5 mL)	Multi-dose vial (5.0 mL)	Single-dose vial (0.5 mL)	Single-dose syringe (0.5 mL)	Single-dose syringe (0.7 mL)
8/29/2023	ABO Pharmaceuticals	(877) 226-2266 marcus@abopharmaceuticals.com			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
8/29/2023	Cardinal Health	fluteam@cardinalhealth.com	✓	✓		✓	✓	✓	✓	✓	✓			✓	✓
8/28/2023	GSK	(866) 475-8222 vaccine.service-center@gsk.com	✓	✓											
8/25/2023	Nationwide Medical Surgical	(818) 997-8848 flu@nmsincusa.com				✓	✓	✓	✓	✓	✓	✓		✓	✓
8/25/2023	Sanofi	(800) 822-2463 www.vaccineshop.com										✓	✓		✓

Note: All information is provided by distributors and manufacturers on a voluntary basis and is not intended to endorse or promote one distributor's/manufacturer's product over another.

IIV4 = quadrivalent inactivated vaccine; ccIIV4 = cell culture-based quadrivalent inactivated influenza vaccine; LAIV = quadrivalent live attenuated influenza vaccine; RIV4 = quadrivalent recombinant influenza vaccine

# RESPIRATORY SYNCYTIAL VIRUS

- IN SEPTEMBER OF 2023, [CDC RECOMMENDED A NEW RSV](#) BIOLOGIC FOR INFANTS THAT HAS BEEN SHOWN TO REDUCE THE RISK OF BOTH RSV-RELATED HOSPITALIZATIONS AND HEALTHCARE VISITS IN INFANTS BY ABOUT 80 PERCENT.
- [V-SAFE](#), ONE OF [SEVERAL SYSTEMS](#) CDC USES TO CLOSELY MONITOR THE SAFETY OF VACCINES, **WILL BE AVAILABLE THIS FALL** TO INCLUDE HEALTH CHECK-INS INITIALLY FOR ADULTS 60 YEARS AND OLDER WHO RECEIVE A [RESPIRATORY SYNCYTIAL VIRUS](#) (RSV) VACCINE AND SOON THEREAFTER FOR PREGNANT PEOPLE WHO RECEIVE A MATERNAL RSV VACCINE.
- **V-SAFE**, ORIGINALLY DEVELOPED IN 2020 FOR PEOPLE TO REPORT HOW THEY FELT AFTER RECEIVING COVID-19 VACCINES, WILL ENABLE PARTICIPANTS TO REPORT HOW THEY FEEL AFTER GETTING AN RSV VACCINE. ADDITIONALLY, ENHANCED FUNCTIONALITY WILL ALLOW PARTICIPANTS TO USE A COMPUTER, SMARTPHONE, OR TABLET TO ENROLL AND COMPLETE HEALTH CHECK-INS.

# RSV VACCINES FOR OLDER ADULTS

- **WHAT TYPES OF RSV VACCINES ARE THERE?**
  - THERE ARE **TWO RSV VACCINES LICENSED** BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR USE IN ADULTS 60 AND OLDER IN THE UNITED STATES:
    - RSVREF3 (AREXVY)
    - RSVREF (ABRYSVO)
- **ELIGIBILITY:** THROUGH SHARED CLINICAL DECISION-MAKING BETWEEN PATIENT AND HEALTH CARE PROVIDER

# RSV BIOLOGICS TO PROTECT INFANTS AND YOUNG CHILDREN

- **MONOCLONAL ANTIBODY PRODUCTS ARE AVAILABLE TO PROTECT INFANTS AND YOUNG CHILDREN FROM SEVERE RSV \***.
  - 1 DOSE OF NIRSEVIMAB FOR **ALL** INFANTS YOUNGER THAN 8 MONTHS BORN DURING OR ENTERING THEIR FIRST RSV SEASON.
  - 1 DOSE OF NIRSEVIMAB FOR INFANTS AND CHILDREN 8–19 MONTHS OLD WHO ARE AT INCREASED RISK FOR SEVERE RSV DISEASE AND ENTERING THEIR SECOND RSV SEASON.
- *NOTE:* A DIFFERENT MONOCLONAL ANTIBODY, PALIVIZUMAB, IS LIMITED TO CHILDREN UNDER 24 MONTHS OF AGE WITH CERTAIN CONDITIONS THAT PLACE THEM AT HIGH RISK FOR SEVERE RSV DISEASE. IT MUST BE GIVEN ONCE A MONTH DURING RSV SEASON. PLEASE SEE [AAP GUIDELINES FOR PALIVIZUMAB](#).

\*

# RSV VACCINES DURING PREGNANCY

## VACCINATION OF PREGNANT INDIVIDUALS:

- **CDC RECOMMENDS A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE FOR PREGNANT PEOPLE TO PROTECT THEIR BABIES FROM SEVERE RSV DISEASE.**
- **PREGNANT PEOPLE SHOULD GET A SINGLE DOSE OF PFIZER'S BIVALENT RSV PREF VACCINE (ABRYSVO) DURING WEEKS 32 THROUGH 36 OF PREGNANCY – BETWEEN SEPTEMBER AND JANUARY**
- **FOR ADDITIONAL INFORMATION:**  
[HTTPS://WWW.CDC.GOV/VACCINES/VPD/RSV/HCP/PREGNANT-PEOPLE.HTML](https://www.cdc.gov/vaccines/vpd/rsv/hcp/pregnant-people.html)

# VACCINE AND TRAINING RESOURCES

- THE FOLLOWING ARE SOME **WAYS YOU CAN PREPARE FOR FALL 2023-2024 SEASONAL RESPIRATORY DISEASES:**
  - ENGAGE YOUR STAFF/TEAM IN LEARNING OPPORTUNITIES WITH [CDC'S IMMUNIZATION EDUCATION AND TRAINING COURSES](#)
  - MAKE YOUR PRACTICE A SUPPORTIVE SPACE THAT WELCOMES [VACCINE QUESTIONS AND CONCERNS FROM PATIENTS AND PARENTS.](#)
  - USE [PROVEN STRATEGIES](#) TO ENCOURAGE PARENTS AND PATIENTS TO STAY CURRENT ON VACCINATIONS. OR CHECK-OUT INNOVATIVE STRATEGIES BEING PILOTED BY IHS CLINICS ACROSS THE COUNTRY THROUGH THE [IHS E3 PROGRAM.](#)

# IHS NATIONAL E3 VACCINE STRATEGY

- **VACCINATION IS THE CLINICAL & PUBLIC HEALTH PREVENTION PRIORITY IN IHS.**
- IHS ADVOCATES THAT **EVERY PATIENT AT EVERY ENCOUNTER** SHOULD BE OFFERED **EVERY RECOMMENDED VACCINE**, WHEN CLINICALLY INDICATED. INCLUSIVE OF ALL ACIP-RECOMMENDED VACCINES.
- WEBPAGE: [HTTPS://WWW.IHS.GOV/NPTC/E3-VACCINE-STRATEGY/](https://www.ihs.gov/nptc/e3-vaccine-strategy/)
  - RESOURCE BANK, E3 CHAMPIONS PILOT, BEST PRACTICES

# RESOURCES

- LATEST INFORMATION ON COVID-19 VACCINE AVAILABILITY AT CERTAIN PROVIDERS OR PHARMACIES: [HTTPS://VACCINES.GOV](https://vaccines.gov)
- NIRSEVIMAB RECOMMENDATIONS PUBLISHED IN MMWR: [HTTPS://WWW.CDC.GOV/MMWR/VOLUMES/72/WR/MM7234A4.HTM](https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm)
- **CDC RESPIRATORY SYNCYTIAL VIRUS (RSV)** IMMUNIZATIONS INFORMATION (INCLUDES INFORMATION ON MATERNAL RSV VACCINE): [HTTPS://WWW.CDC.GOV/VACCINES/VPD/RSV/INDEX.HTML](https://www.cdc.gov/vaccines/vpd/rsv/index.html)
- ADVISORY COMMITTEE ON IMMUNIZATION PRACTICE (ACIP) SLIDES: [HTTPS://WWW.CDC.GOV/VACCINES/ACIP/MEETINGS/SLIDES-2023-08-3.HTML](https://www.cdc.gov/vaccines/acip/meetings/slides-2023-08-3.html) AND [HTTPS://WWW.CDC.GOV/VACCINES/ACIP/MEETINGS/SLIDES-2023-09-22.HTML](https://www.cdc.gov/vaccines/acip/meetings/slides-2023-09-22.html)
- ACCESS TO **VACCINE INFORMATION STATEMENTS (VIS)**: [HTTPS://WWW.CDC.GOV/VACCINES/HCP/VIS/INDEX.HTML](https://www.cdc.gov/vaccines/hcp/vis/index.html)
- **IHS E3 VACCINE STRATEGY** WEBPAGE: [HTTPS://WWW.IHS.GOV/NPTC/E3-VACCINE-STRATEGY/](https://www.ihs.gov/nptc/e3-vaccine-strategy/)
- CDC'S INTERIM CLINICAL CONSIDERATIONS PAGE FOR MORE INFORMATION:  
[HTTPS://WWW.CDC.GOV/VACCINES/COVID-19/CLINICAL-CONSIDERATIONS/INTERIM-CONSIDERATIONS-US.HTML](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html)

# QUESTIONS ?

SUSAN DUCORE, DNP, MSN, RN, PHN

[SUSAN.DUCORE@IHS.GOV](mailto:SUSAN.DUCORE@IHS.GOV)

AREA NURSE CONSULTANT/PROJECT OFFICER

AREA IMMUNIZATION COORDINATOR

CAIHS PROGRAM DIRECTORS' MEETING\_ OCTOBER 4, 2023